Medicxi backs siRNA-focused Aldena Therapeutics with $30M

With a $30 million infusion into Aldena Therapeutics by Medicxi, siRNA-based therapies are moving into dermatology.

Aldena, founded in 2021, plans to use its pipeline of six different compounds on skin diseases focusing on atopic dermatitis, vitiligo, alopecia areata and psoriasis. Three of the compounds will be ready for IND filing next year, and two of the lead compounds will initially focus particularly on alopecia areata and atopic dermatitis.